背景:由于区分模棱两可的痣的主观性,诊断侵袭性皮肤黑色素瘤(CM)可能具有挑战性,黑色素瘤原位和薄CMs从痣进展为黑色素瘤的潜在分子机制必须得到更好的理解。确定治疗反应的生物标志物,诊断和预后至关重要。使用来自生物库的生物医学数据和基于人群的医疗保健数据,转化研究可以通过实施循证研究来改善患者护理。BioMEL生物银行是一个潜在的,多中心,关于模棱两可的痣和原发性黑色素瘤转移的所有阶段的大规模生物医学数据库。它的目的是作为翻译资源,使研究人员能够发现客观分子,基因型,痣和黑色素瘤所有阶段的表型和结构差异。主要目标是利用BioMEL显着改善诊断,黑色素瘤患者的预后和治疗结果。
方法:BioMEL生物样本库包含生物样本,接受黑色素瘤常规治疗的成年患者的流行病学信息和医学数据。BioMEL专注于原发性和转移性黑色素瘤,但也包括不明确的色素性病变,如临床上非典型痣和原位黑色素瘤。BioMEL数据是通过问卷调查收集的,采血,肿瘤成像,组织取样,病历和组织病理学报告。
背景:BioMEL生物库项目已获得瑞典国家道德审查局(Dnr。2013/101、2013/339、2020/00469、2021/01432和2022/02421-02)。由于与伦理审查机构相关的规定,生成的数据集不可公开。
背景:NCT05446155。
Diagnosing invasive cutaneous melanoma (CM) can be challenging due to subjectivity in distinguishing equivocal nevi, melanoma in situ and thin CMs. The underlying molecular mechanisms of progression from nevus to melanoma must be better understood. Identifying biomarkers for treatment response, diagnostics and prognostics is crucial. Using biomedical data from biobanks and population-based healthcare data, translational research can improve patient care by implementing evidence-based findings. The BioMEL biobank is a prospective, multicentre, large-scale biomedical database on equivocal nevi and all stages of primary melanoma to metastases. Its purpose is to serve as a translational resource, enabling researchers to uncover objective molecular, genotypic, phenotypic and structural differences in nevi and all stages of melanoma. The main objective is to leverage BioMEL to significantly improve diagnostics, prognostics and therapy outcomes of patients with melanoma.
The BioMEL biobank contains biological samples, epidemiological information and medical data from adult patients who receive routine care for melanoma. BioMEL is focused on primary and metastatic melanoma, but equivocal pigmented lesions such as clinically atypical nevi and melanoma in situ are also included. BioMEL data are gathered by questionnaires, blood sampling, tumour imaging, tissue sampling, medical records and histopathological reports.
The BioMEL biobank project is approved by the national Swedish Ethical Review Authority (Dnr. 2013/101, 2013/339, 2020/00469, 2021/01432 and 2022/02421-02). The datasets generated are not publicly available due to regulations related to the ethical review authority.
NCT05446155.